Covid vaccine developer to start clinical trial this month

Oral Covid vaccine hopeful Vaxart Inc. will start enrolling people in its first clinical trial this month against the deadly viral killer. Shares of the South San Francisco company (NASDAQ: VXRT) jumped as much as 60% Monday to $8.47 from Friday's close after Vaxart said the Food and Drug Administration greenlighted its trial plan. Shares settled at $7.78 per share, up 47%. Vaxart's approach stands out against conventional vaccines because it is oral, so it could be distributed more easily and…

Click to view original post